Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Bioinformatics analysis of aberrantly methylated-differentially expressed genes and pathways in hepatocellular carcinoma

Published:2018-06-28 Issue:24 Volume:24 Page:2605-2616
ISSN:1007-9327
Container-title:World Journal of Gastroenterology
language:
Short-container-title:WJG

Author:

Sang Liang,Wang Xue-Mei,Xu Dong-Yang,Zhao Wen-Jing

Publisher

Baishideng Publishing Group Inc.

Subject

Gastroenterology,General Medicine

Reference48 articles.

1. Tian J, Hu X, Gao W, Zhang J, Chen M, Zhang X, Ma J, Yuan H. Identification a novel tumor-suppressive hsa-miR-599 regulates cells proliferation, migration and invasion by targeting oncogenic MYC in hepatocellular carcinoma. Am J Transl Res 2016; 8: 2575-2584

2. Global cancer statistics, 2012

3. Parallel epigenetic and genetic changes in the pathogenesis of hepatitis virus-associated hepatocellular carcinoma

4. Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma

5. Mutational landscape and significance across 12 major cancer types

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Alteration in DNA methylation patterns: Epigenetic signatures in gastrointestinal cancers;European Journal of Pharmacology;2024-06

2. The role of Cyclin Dependent Kinase Inhibitor 3 (CDKN3) in promoting human tumors: Literature review and pan-cancer analysis;Heliyon;2024-02

3. MiR-96-5p Suppresses Progression of Arsenite-Induced Human Keratinocyte Proliferation and Malignant Transformation by Targeting Denticleless E3 Ubiquitin Protein Ligase Homolog;Toxics;2023-12-01

4. Comprehensive Analysis Reveals the Potential Roles of CDKN3 in Pancancer and Verification in Endometrial Cancer;International Journal of General Medicine;2023-12

5. Identification of biomarkers of renal ischemia-reperfusion injury by bioinformatics analysis and single-cell sequencing analysis combined with in vivo validation;Transplant Immunology;2023-12